Clinical trials: Malignancies Multiple
Carcinoma in Situ, Transitional Cell Carcinoma
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin…
- Conditions
- Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT01310803
- Testing
- VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care)
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Patients With Multiple Myeloma Experiencing a, First or Second Relapse
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
- Trial name
- KIRIMID (NCT01217203)
- Testing
- IPH2101 combined to lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Innate Pharma
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
- Conditions
- B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT00446342
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sunesis Pharmaceuticals
Metastatic Pancreatic Cancer
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
In Phase 1b study, six subjects will be enrolled in Arm A (YL-13027 + AG regimen) and Arm B (HY-0102 + AG regimen). The first 12 subjects will be evaluated for safety after one cycle.
- Trial name
- NCT06662669
- Testing
- YL-13027, HY-0102, Gemcitabine
- Volunteers
- 120 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Glioma
Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma
A study to demonstrate safety, and feasibility for intraparenchymal injection of irinotecan hydrochloride drug-eluting beads in the treatment of recurrent high grade glioma (HGG).
- Trial name
- IDEB-glioma (NCT02481960)
- Testing
- CM-BC2 Irinotecan drug-eluting bead
- Where
- 2 sites in France, Germany
- Volunteers
- 5 people
- Sponsor
- Boston Scientific Corporation
Multiple Brain Metastases
A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain…
- Trial name
- NCT03608020
- Testing
- BMX-001, Whole Brain Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- BioMimetix JV, LLC
Carcinoma, Renal Cell
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00334282
- Testing
- Pazopanib
- Where
- 99 sites in Argentina, Australia and 23 more
- Volunteers
- 435 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma in Relapse, Multiple Myeloma (MM)
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07735546
- Testing
- UB-VV500, Rapamycin (sirolimus)
- Volunteers
- 100 people
- Sponsor
- Umoja Biopharma
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Rectal Polyp, Rectal Polyps
Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device
The aim of the clinical trial is to investigate whether the use of a new multichannel endoscopic transanal access device (named UNI-VEC) is safe and effective in the resection of a rectal polyp or tumor that sits in the distal…
- Conditions
- Rectal Polyp, Rectal Polyps, Rectal Lesion, Sessile Colonic Polyp
- Trial name
- UNI-VEC (NCT06286956)
- Testing
- Treatment of rectal lesions with UNI-VEC
- Where
- 11 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Vecmedical Spain, S.L.
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Multiple Myeloma (MM)
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
- Trial name
- LINKER-MM8 (NCT07428369)
- Testing
- Linvoseltamab, Bortezomib, Lenalidomide
- Sponsor
- Regeneron Pharmaceuticals
Breast Neoplasm Female, Breast Cancer
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
Breast conserving surgery (BCS) is performed on patients with breast cancer to resect and completely remove the cancer while conserving as much of the surrounding healthy tissue as possible.
- Trial name
- NCT04815083
- Testing
- Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- SBI ALApharma Canada, Inc.
Melanoma
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV…
- Trial name
- NCT05116202
- Testing
- Nivolumab, Ipilimumab, RO7247669 2100 mg
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Neoplasm Metastasis
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
- Trial name
- NCT04458259
- Testing
- PF-07265807, Sasanlimab, Axitinib
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 88 people
- Sponsor
- Pfizer
Multiple Myeloma, Relapse Multiple Myeloma
Descartes-25 in Relapsed/Refractory Multiple Myeloma
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in…
- Trial name
- NCT05113342
- Testing
- Descartes-25
- Where
- 3 sites in United States, Turkey (Türkiye)
- Volunteers
- 9 people
- Sponsor
- Cartesian Therapeutics
Relapsed or Refractory Non-Hodgkin Lymphoma
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.
- Trial name
- NCT06845241
- Testing
- ICP-490
- Where
- 6 sites in China
- Volunteers
- 68 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Multiple Myeloma
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Multiple myeloma is a disease that resides primarily in the bone and has shown to be sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as Holmium-166-DOTMP, in conjunction with melphalan…
- Trial name
- NCT00039754
- Testing
- Holmium-166-DOTMP
- Sponsor
- Poniard Pharmaceuticals
Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications
THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells in seven refractory cancers…
- Trial name
- THINK (NCT03018405)
- Testing
- NKR-2 cells
- Where
- 5 sites in United States, Belgium
- Volunteers
- 146 people
- Sponsor
- Celyad Oncology SA
Breast Cancer, Neutropenia
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.
- Trial name
- NCT01648322
- Testing
- F-627, Neulasta® (pegfilgrastim)
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- EVIVE Biotechnology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.